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ABSTRACT 
Objective: The combination therapy of ethinylestradiol and testosterone in post-menopausal females has shown improved sexual response and 
libido. The present studies were designed to develop a suitable matrix-type transdermal drug delivery system (TDDS) of ethinylestradiol and 
testosterone using the polymer chitosan. 
Methods: Five formulations (ET1 to ET5) were developed by varying the concentration of polymer and keeping the drug load constant. Physical 
parameters and drug excipient interaction studies were evaluated in all the formulations. In vitro skin permeation profiles of ethinylestradiol and 
testosterone from various formulations were simultaneously characterized in a thermostatically controlled modified Franz Diffusion cell using 
HPLC. Based on the physical parameters and in vitro skin permeation profile formulation ET3 containing 30 mg/ml of chitosan was found to be the 
best and chosen for further studies. Optimized formulation was subjected to in vivo pharmacokinetic analysis in rats using ELISA. 
Results: Stability profile of patch formulation ET3 depicted stability up to 3 mo. One week skin irritation evaluation in rats indicated that 
formulation ET3 was nonirritating. Combination transdermal patch across rat skin showed a maximum release of 92.936 and 95.03 % in 60 h with a 
flux of 2.088 and 21.398 µg/cm2h for ethinylestradiol and testosterone respectively. 
Conclusion: The net result of this study is the formulation of a stable, non-irritating transdermal patch of ethinylestradiol and testosterone, with 
good bioavailability and can be used as Estrogen Replacement Therapy (ERT) in postmenopausal women. 
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The concept of delivering drugs through the skin for systemic 
treatment of diseased states is gaining increasingly great importance 
due to its advantages [1]. The advantages of TDDS are bypassing of 
hepatic first-pass metabolism, enhancement of therapeutic 
efficiency, prolonged duration of action of potent drugs with short 
plasma half-life and maintenance of steady plasma or serum level of 
the drug. However, transdermal delivery is limited to drugs having 
low doses, low melting points, and molecular weights and solubility 
of greater than 1 m g/ml in both water and mineral oil [2]. 
Ethinylestradiol and testosterone both play a significant role in 
regulating female sexual function. The most common complaints 
associated with decreased estrogen and/or testosterone levels are 
decreased desire and libido, vaginal dryness and lack of sexual 
arousal in postmenopausal females [3-13]. The estimated 
proportion of women who can be classified as having low sexual 
desire ranges from 7 to 33%, depending on the population studied 
and the definition being used [8, 14]. Due to a hormonal deficiency 
in postmenopausal women, Hypoactive Sexual Desire Disorder 
(HSDD) is commonly reported [3, 15-17]. Estrogen replacement 
therapy improves sexual function in females in conjunction with 
testosterone. In plasma, testosterone is largely bound to Serum 
Hormone Binding Globulin (SHBG). Estrogen Replacement Therapy 
(ERT) increases SHBG production: therefore, it is plausible that 
postmenopausal women treated with exogenous estrogen have less 
available free testosterone than untreated women [18]. This may 
subsequently lead to a decrease in sexual function in women who 
are treated with ERT [18-21]. Postmenopausal women who have 
failed to correct their sexual function with ERT alone can improve 
their sexual response treated additionally with testosterone [3, 10, 
19-22]. Moreover, ethinylestradiol and testosterone possess most of 
the ideal physicochemical and biological properties to be formulated 
into a transdermal patch type delivery system like small t½, (in 
minutes), small daily dose in (in µg/day) [10, 23] and hepatic first-
pass effect upon oral administration. But so far, no work related to 
the development of transdermal patches of ethinylestradiol and 
testosterone in combination has been reported. The present 
investigation was designed to develop a suitable matrix patch [24] 
type TDDS for ethinylestradiol and testosterone employing varied 
amounts of chitosan. Chitosan is widely acknowledged to be non-
toxic even at relatively high concentrations in vivo and in vitro. 
Chitosan is a cationic polymer that exhibits several unique 
properties, which are desirable features of TDDS. Chitosan may act 
as penetration enhancer to improve the permeability of drugs across 
the underlying tissue by its effects on tight junctions [25-28]. The 
aim of the present study was to optimize the concentration of 
polymer for a suitable delivery system in terms of in vitro and in vivo 
skin permeation of drugs and to find out the best possible 
concentration of polymer, which may be chosen for further studies.  
MATERIALS AND METHODS 
Materials 
Chitosan and ethinylestradiol were received as a gift sample from 
Central Cochin Fisheries Ltds., Cochin and Ontop Pharmaceuticals 
ltd., Bangalore. Testosterone was purchased from Sigma Aldrich, 
India. methanol (HPLC grade) (SD Fine Chemical Ltd, Mumbai, 
disodium hydrogen phosphate A. R grade, potassium dihydrogen 
orthophosphate (CDH (P) Ltd New Delhi), gum acacia (Pioneer 
Chemical Co., Delhi) were also procured. All chemicals were used as 
received without any further purification. 
Preparations of films 
Transdermal films of ethinylestradiol (2.5 mg) and testosterone (25 
mg) were prepared by varying the concentration of chitosan (20, 25, 
30, 35 and 40 mg/ml) and keeping the drug load constant. 
Bioadhesive film was prepared by a solvent casting method. The 
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chitosan was accurately weighed and transferred to a l 0 ml beaker; 
to this 5 ml of 4%, (v/v) lactic acid (as a solvent and permeation 
enhancer) was added. The beaker was kept on magnetic stirrer to 
dissolve the polymer. The mixture was stirred continuously stirred 
to prevent the formation of lumps of polymer and stirring was 
continued till a clear solution was obtained. To this 25 mg of 
testosterone was added and the stirring was continued. After 24h of 
stirring. 2.5 mg of ethinylestradiol was added, and the stirring was 
continued for another 24 h. The resulting solution was then 
transferred onto the Teflon coated mould (15 cm2). The mould was 
covered with an inverted funnel to control the rate of evaporation of 
the solvent system and kept undisturbed overnight for drying. The 
dried patches were kept in desiccators until use. 
Drug-polymer interaction study 
The physicochemical compatibility between ethinylestradiol and 
testosterone and polymers used in the films was studied by using 
Fourier transform-infrared (FT-IR-8400, Shimadzu Co., Japan) 
spectroscopy. The pellatization was done by the KBr pellet method. 
The FT-IR spectra were recorded in the wavelength region between 
4000 and 400 cm-1. The spectra obtained for ethinylestradiol and 
testosterone and physical mixtures of ethinylestradiol and 
testosterone with polymers were compared. 
Differential scanning calorimetry 
About 5 mg of sample was weighed and crimped into an aluminum 
pan and analyzed at scan range from 0 °C–300 °C at the heating rate 
of 5 °C/min under a nitrogen flow of 25 ml/min 
Physical characteristics of the prepared films 
The thickness of each patch was measured at different sites using 
Membrane Thickness Gauge, and the average thickness was calculated. 
Patches were evaluated for their physical appearance and graded as 
opaque/transparent/smooth/wrinkled/moist/dry/flexible/tough/sti
cky/non-sticky. 
Each patch was cut into six patches of 1 cm2 area and weighed. The 
average weight was calculated, and percentage deviation of each 1 
cm2 patch from average weight was determined. Folding endurance 
was determined by repeatedly folding the film at the same place 
until it broke. The number of times the film could be folded at the 
same place without breaking was the folding endurance value. 
Flatness was determined as thee longitudinal strips were cut out 
from each film. The length of each strip was measured and the 
variation in length because of non-uniformity in flatness was 
measured by determining percent constriction with 0% constriction 
equivalent to 100% flatness [29]. 
Percentage of constriction = (I1-I2)/I2×100 
Where, l 1= initial length of each strip and 
I2= final length of each strip 
Percentage moisture absorption 
The films were weighed accurately and placed in the desiccator 
containing 100 ml of saturated solution of potassium chloride, which 
maintains 84.34% RH at 25 °C. After 3 d the films were taken out 
and weighed. The percentage moisture absorption was calculated 
using the following formula [2]- 
Percentage of moisture content = X-Y/Y × 100 
Where, X = initial weight, Y = final weight. 
Drug content uniformity 
An accurately cut patch of 1 cm2area was taken and added to the 
beaker containing 10 ml saline solution. The beaker was kept for 24 
h with occasional shaking. The samples were analyzed for drug 
content using HPLC at 244 and at 280 nm for testosterone and 
ethinylestradiol respectively [39]. 
In vitro skin permeation studies 
The in vitro skin permeation studies of ethinylestradiol and 
testosterone from TDDS though rat skin was conducted using a 
modified Franz Diffusion cell. Protocols for all animal experiments 
were approved by the Institutional Animal Ethics Committee. 
Methanol: phosphate Buffer saline, pH 7.4 in the ratio of 7.3 was 
used as a receptor fluid in the receptor compartment of the cell. 
Rat’s abdominal skin was excised, hair was removed using scissors, 
and fatty tissues attached to dermis were removed carefully [40, 41]. 
The skin was mounted between donor and receiver compartment of 
the diffusion cell having capacity 20 ml, with the epidermis facing 
upward into the donor compartment. The test film of 1.5 cm2area 
was placed on the acclimatized skin. The bathing solution in receiver 
compartment was agitated with a magnetic stirrer at a temperature 
of 37±1 °C maintained thermostatically. Samples (l ml in each case) 
were withdrawn at regular intervals, and fresh receptor fluid was 
added to maintain a constant volume of receptor fluid. The Samples 
were analyzed at 280 and 244 nm, for ethinylestradiol and 
testosterone respectively using HPLC (LC Solutions Shimadzu, 
Japan) and drug contents were determined from the calibration 
curve. Calibration curves for both the drugs were obtained using 
HPLC equipped with a Prominence diode-array detector. A 
purospher STAR, merck RP 18C Pre-packed column (5 μm, 250 mm 
4 mm i. d) was used as an analytical column. Methanol: water 
(70:30) combination after optimization was used as the mobile 
phase at a flow rate oflml/minl ml/min. The analytical column was 
maintained at 37 °C the same temperature as for drug release and skin 
permeation studies to minimize the potential drug precipitation in the 
column. A 20 µl sample volume was injected each time though a 
manual injector using Hamilton microlitre syringe. The 
chomatographic peaks for ethinylestradiol and testosterone were well 
resolved at retention times (RT) at 6.6 and 8.6 min. respectively. 
Stability evaluation 
Stability studies were performed for 3 mo using optimized 
formulation ET3. All the stability samples (packed in aluminum foil) 
were prepared in triplicates and were kept at two stability testing 
conditions: viz. Accelerated (40±2 °C/75%±5%RH) and 
Intermediate (30±2 °C/65%±5%RH) as per (ICH) Q1AR2 guidelines 
[30]. Stability samples were evaluated for drug excipient interaction 
and in vitro permeation through human cadaver epidermis at the 
following time points; initial, 1st, 2nd and 3rd month [42]. 
Skin irritation studies 
The optimized transdermal patches were evaluated for primary skin 
irritation studies on rats. All the experimental procedures were 
approved by the Institutional Animal Ethics Committee (IAEC). All the 
experimental procedures were carried out in accordance with the 
committee for the purpose of control and supervision of experiment on 
animal guidelines (125/2013/CPCSEA). Wistar rat’s hairs were removed 
by shaving from the dorsal area one day before the test. The rats were 
divided into 4 groups (n= 6). Group, I served as the control (without any 
treatment), Group II received optimized medicated transdermal patch, 
Group III received a blank transdermal patch and Group IV applied with 
a 0.8% v/v aqueous solution of formalin as a standard irritant [31]. A 
new patch, or new formalin solution, was applied at Ist, 4th and at 7th 
day. The patch was secured using an adhesive tape. These patches were 
covered with an occlusive covering to approximate the condition of use. 
Finally, the application sites were graded for any sign of erythema or 
edema according to a visual scoring scale. 
RESULTS AND DISCUSSION 
Transdermal Therapeutic Systems are self-contained, discrete 
dosage forms which, when applied to the intact skin, deliver the 
drug(s), though the skin, at a controlled rate to the systemic 
circulation. Testosterone has been combined with ethinylestradiol 
since ERT alone leads to a decrease in free testosterone level. TDDS 
have been designed for controlled drug delivery with the intention 
of maintaining constant plasma levels. 
The physicochemical studies like the percentage moisture 
absorption, flatness, folding endurance etc. provide information 
regarding the stability of the formulations. Formulations ET 1-5 
contained fixed amount of testosterone (25 mg) and ethinylestradiol 
(2.5 mg) and polymer (chitosan) concentration was varied from 20-
40 mg/ml respectively. The area of the patch was 15 cm2 (table 1). 
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The physical appearance of the various formulations in terms of 
their transparency, smoothness, flexibility, stickiness, homogeneity 
and opaque properties were recorded, and formulation ET3 was 
found to be uniform, translucent, slightly sticky and flexible. The 
percentage of moisture absorption, average thickness, and weight 
varied to a small extent in all formulations studied. 
 















Average drug content (%)a 
Testosterone Ethinylestradiol 
ET1 21.5±0.36 0.070±0.008 100 372±8 15 92±4.3 96±4.8 
ET2 22.6±0.72 0.074±0.007 100 381±9 18 87±4.8 94±5.4 
ET3 22.9±0.39 0.076±0.008 100 390±11 16 93±4.2 96±6.2 
ET4 23.2±0.45 0.081±0.009 100 367±7 20 88±5.3 95±5.8 
ET5 23.2±0.45 0.083±0.005 100 400±9 23 89±5.1 91±3.7 
amean±SD, n = 3. 
 
Matrices properties 
The weight variations of the patches were in the range of 20.6 
mg/cm2 to 22.9 mg/cm2 for 5 formulations, the difference in weight 
variation was due to the addition of polymer in different ratios 
which influence weight of patches. The results are given in table 1. 
The thickness of the transdermal patches ET l-ET5 for 5 different 
polymer ratios varied from 0.070±0.008 mm to 0.083±0.005 mm. 
The maximum difference between the thicknesses of patches was 
0.013 mm, which indicates that all the prepared patches were of 
nearly uniform thickness. The results are given in table 1. 
All the formulations ET1-ET5 showed 100% flatness which indicates 
0% constriction of the formulated patches (table 1). Test results 
indicated that all the patches can withstand to rupture and would 
maintain their integrity with general folding when used. The folding 
endurance values lie in between 372 and 400 and were measured 
manually. The value was found to be high in patches containing a 
higher amount of the chitosan. The prepared transdermal patches 
showed good tensile strength and there was no sign of cracking in 
the prepared transdermal film. Mechanical properties of a polymer 
matrix were improved by the use of polymers. 
Tensile strength lies in between 372 g/cm2 and 400 g/cm2, the 
difference in values were due to the composition of polymer used. 
Also, there was an increase in the tensile strength with increasing 
concentration of chitosan. Highest tensile strength was observed in 
ET5, and this might be due to the highest concentration of 
hydrophilic polymer used and as the concentration decreased from 
ET5 to ET1tensile strength got decreased. The results are given in 
table 1. 
The percentage moisture absorption was calculated which was 
found to be as 15 to 23% for ET1-ET5 respectively (table 1). There 
was an increase in moisture absorption with an increase in the 
amount of hydrophilic polymer, chitosan. Similarly, the thickness 
and weight of patch were found to be increased accordingly. 
The drug content varied due to polymers which were added in 
different concentrations. As the polymer concentration increases, 
the bond formation between the drug molecules and polymer 
molecules increases which will retard the drug release. The drug 
content of ethinylestradiol in formulations ETl-ET5 varied from 91-
96 % (table l) the drug content of testosterone in formulations ET1-
ET5 varied from 88-96 %. (table 1). This demonstrates the 
homogenous distribution of the drugs. 
The FTIR and DSC scans of the patch containing drugs and patch 
without drug were obtained to assess any interaction between drug 
and excipients. On analysis of the FTIR spectra of the pure drug and 
the medicated formulation, no major difference was observed in the 
absorption peak pattern. The DSC of patch gave an endothermic 
peak of testosterone at l46 °C (pure drug-149 °C), and an 
endothermic peak of ethinylestradiol at 184 °C (pure drug-185.13 
°C) and this confirmed the purity of drug sample used. The DSC data 
suggested that possibly there was no chemical interaction between 
drugs with patch forming polymer/materials. The HPLC spectrum 
showed absorption maxima at 244 nm for testosterone and an 
absorption maximum at 280 nm for ethinylestradiol with RT-8.6 and 
6.6 min respectively (fig. 1 and 2). 
 
 
Fig. 1: HPLC chromatogram of testosterone showing retention 
time (RT) and Area under curve (AUC) at 244 nm 
 
 
Fig. 2: HPLC chromatogram of ethinylestradiol showing a 
retention time (RT) and Area under the curve (AUC) at 280 nm 
 
Drug release 
The permeability of ingredients was evaluated using modified Franz 
diffusion Cell. The formulation showed the variable release pattern. 
The process of drug release in most of the controlled release devices 
including transdermal patches is governed by diffusion In vitro 
release profile of ethinylestradiol and testosterone across rat skin 
was maximum f'rom the formulation ET3, with 92.936 % of 
ethinylestradiol at the end of' 60 h (fig. 3) and 95.033 % of 
testosterone at the end of 60 h (fig. 4) with flux of 2.088 for 
ethinylestradiol and 21.398 µg/(cm2 h) for testosterone. The in vitro 
skin permeation studies using cadaver skin as rate limiting membrane 
for formulation ET3 showed a maximum release of 80.456±1.64 % 
ethinylestradiol in 60 h with a flux of 1.938±10.52 µg/(cm2h) and 
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79.51±1.05% testosterone in 60 h with a flux of 18.673±0.8l 
µg/(cm2h) (table 2). The studies indicated that the overall permeation 
rate in rat skin is higher than that in the cadaver skin. 
This showed that the formulations with increased concentrations of 
chitosan resulted in sustained release of the drug up to a certain 
level and furthermore decreased due to excess polymer 
concentration which resulted in high encapsulation of drug. 
Formulations ET1, ET 2, ET 4 and ET5) with varied polymer 
concentration, showed a constant increase and then decrease in the 
cumulative drug release due to drug degradation by the excess 
moisture content and uptake. 
 
 
Fig. 3: Comparative permeation profiles of Ethinylestradiol from different patch formulations across rat skin. mean±SD, n = 3 
 
 
Fig. 4: Comparative permeation profiles of testosterone from different patch formulations across rat skin, mean±SD, n = 3 
 
Table 2: Release kinetics 
Formulation Zero order R2* First order R2* Higuchian plot R2* 
Ethinylestradiol Testosterone Ethinylestradiol Testosterone Ethinylestradiol Testosterone 
ET1 0.881 0.937 0.852 0.894 0.992 0.998 
ET2 0.943 0.905 0.847 0.868 0.997 0.986 
ET3 0.903 0.922 0.943 0.879 0.9767 0.985 
ET4 0.974 0.903 0.921 0.864 0.984 0.979 
ET5 0.956 0.887 0.936 0.898 0.978 0.996 
*R2 values are determination coefficients 
 
On the basis of physicochemical parameters and drug release 
content out of five formulations made, ET3 (150 mg chitosan) was 
selected for further studies and was considered as optimized 
formulation. Comparison of R2 values was made in order to assess 
the nature of the release profile of the formulations. The respective 
R2 values for formulation ET I to ET5 was found to be 0.881, 0.943, 
0.903, 0.974and 0.956 respectively for zero order release plot of 
ethinylestradiol and 0.937, 0.905, 0.922, 0.903 and 0.887 
respectively for zero order release plot of testosterone. (table 2) 
High R2 values with zero order plots indicating a zero order release 
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pattern from the formulations. Optimized formulation (ET3) was 
further subjected to first order and Higuchian regression 
parameters to find a best-fit model for the formulation. The 
regression coefficient value of the first-order plot for formulation 
ET3 was 0.94 ethinylestradiol and 0.8795 testosterone. The 
regression coefficient for Higuchian plot was 0.9767 ethinylestradiol 
and 0.9851 testosterone. Linear curves were obtained on plotting 
the graphs of cumulative percentage drug released versus square 
root of time suggesting Higuchian matrix diffusion mechanism of 
drug release from the TDDS formulation. The results are depicted in 
table 2. The drug release kinetics studies showed that all 
formulations were governed Higuchian model and the release was 
non-Fickianmediated. Regression analysis of the in vitro permeation 
curves was carried out. The slope of the curve obtained after 
plotting the mean cumulative amount released per patch versus 
time was taken as the in vitro release for ethinylestradiol and 
medroxyprogesterone acetate. 
Skin irritation studies 
The optimized transdermal formulation ET3 was evaluated for 
skin irritation studies on rats. The patches were removed after 
48 h, and the area was examined for any signs of skin sensitivity 
or irritation and the fresh patches were secured at the same site 
at 1st,4th and 7th day which is a modification over the method of 
Draize et al., 1946 [38]. No signs of erythema and edema were 
observed in case of patch group. There was a significant 
difference (P<0.01) observed between the patch and the 
formalin treated group (table 3). 
 
Table 3: Visual scores of skin irritation amongst various groups 








(0.8% aq. Solution) 
Eythema 0.00±0.00 1.167±0.408** 1.50±0.548** 3.333±0.516 
Edema 0.00±0.00 1.167±0.753** 1.333±0.816** 3.167±0.753 
All values are reported as (mean value±SEM) (n=6), **represents P<0.01 (very significant) in comparison to group IV 
 
Stability 
The optimized ET3 patches were properly packed in aluminum 
foil and kept for stability studies as per ICH guidelines. 
Transdermal patch was studied for three months at intermediate 
and accelerated conditions (table 3). The physicochemical 
analysis, in vitro permeation across cadaver skin, FTIR and DSC 
analysis at the end of each month were conducted to assess the 
stability of formulations during intermediate and accelerated 
conditions. 
 
Table 3: Permeation profiles (Mean % cumulative release±SD)a of patch ET3 during accelerated stability study across cadaver skin 
Time 
(h) 
Zero month First month Second month Third month 
E T E T E T E T 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 6.97±1.02 6.48±1.79 6.87±0.91 6.47±0.62 6.84±0.87 6.47±2.35 6.84±1.58 6.46±1.64 
2 10.19±0.34 11.25±1.36 10.02±0.96 11.25±0.50 10.00±0.88 11.25±2.51 10.00±1.76 11.25±1.48 
4 19.84±0.41 18.53±0.62 19.78±1.07 18.51±0.99 19.77±0.94 18.50±1.29 19.75±1.63 18.50±1.69 
6 23.99±0.55 23.18±1.57 22.95±1.08 23.12±1.82 21.94±1.57 23.11±1.48 21.91±2.57 23.10±1.34 
8 30.95±0.48 22.36±2.99 30.95±0.25 22.35±0.95 30.78±2.84 22.34±1.64 30.71±2.18 22.33±1.82 
10 37.44±1.12 30.47±3.05 37.44±0.39 30.46±3.78 37.31±1.28 30.46±1.98 37.31±2.65 30.44±2.15 
12 42.15±0.89 34.31±3.24 42.15±0.44 34.32±2.45 42.02±1.36 34.30±0.65 42.00±2.95 34.30±2.65 
16 43.35±0.67 40.99±2.58 42.98±0.70 40.99±3.48 42.24±1.59 40.97±0.48 42.23±1.52 40.96±2.94 
20 49.57±0.78 44.71±2.46 49.57±0.69 44.70±2.51 49.45±1.24 44.68±0.95 49.45±1.87 44.65±3.54 
24 53.22±1.10 48.24±0.73 53.22±0.61 48.21±1.68 53.22±2.65 48.20±0.69 53.21±1.94 48.20±0.65 
28 52.54±1.58 50.25±0.88 53.01±0.54 50.23±1.45 53.02±2.58 50.23±1.25 53.00±1.68 50.23±0.97 
32 59.49±1.91 55.36±066 59.43±0.81 55.34±1.82 59.42±1.92 55.32±1.59 5942±1.81 55.30±0.65 
36 63.96±2.27 62.16±1.83 63.96±0.70 62.15±1.24 63.95±1.43 62.13±1.86 63.93±1.37 62.11±1.57 
42 71.44±2.59 65.72±1.08 71.44±2.10 65.72±1.76 71.43±1.53 65.70±1.67 71.43±1.52 65.70±1.83 
48 73.12±2.63 66.83±0.79 73.12±2.24 66.83±1.84 73.11±2.64 66.81±1.23 73.10±0.69 66.80-±1.94 
54 77.54±1.55 68.51±0.40 77.54±0.62 68.50±0.62 77.53±2.84 68.49±1.51 77.53±0.94 68.481.64± 
60 80.45±0.67 79.51±1.64 80.45±1.36 79.50±1.36 80.05±2.41 79±2.59 80.00±1.51 78.80±1.83 
66 78.21±1.56 72.54±2.11 78.21±0.99 72.52±0.64 78.20±1.58 72.50±1.94 78.18±1.67 72.50±1.24 
72 74.24±0.98 66.28±1.97 74.24±0.98 66.28±1.47 74.21±2.02 66.25±1.85 74.20±1.59 66.23±1.06 
amean±SD, n = 3. 
 
CONCLUSION 
Testosterone has been combined with ethinylestradiol as ERT 
(Estrogen Replacement Therapy) alone leads to a decrease in 
free for testosterone level. Total testosterone production 
decreases by around 25% after menopause. Since 
ethinylestradiol and testosterone both play a significant role in 
regulating female sexual function and hence, been successfully 
combined in a single patch. Amongst the five formulations 
studied, formulation ET3 showed release profile of above 90% at 
the end of 60 h with 92.93 % of ethinylestradiol and 95.03% of 
testosterone across rat skin and 80.45% of ethinylestradiol and 
79.51 % of testosterone across cadaver skin. The optimized 
patch was physicochemical stable and had non-irritating nature 
when applied on rat skin. Further, it can be reasonably 
concluded that chitosan polymer in 30 mg/ml concentration is 
better suited over other concentrations used for the 
development of TDDS of ethinylestradiol and testosterone for 
HSDD in postmenopausal women. The net result of this study is 
the formulation of a stable, non-irritating transdermal patch of 
ethinylestradiol and testosterone, with good bioavailability and 
the optimized formulation (ET3) may be used for further 
pharmacodynamics studies in suitable animal models. 
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